Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Total Non-GAAP Operating Expense Adjustments by Quarter
Total Non-GAAP Operating Expense Adjustments ($M) ($M)
Amgen Total Non-GAAP Operating Expense Adjustments: -$1,098M in Q2 2026, down 32.9% from a year earlier.
Latest, Q2 2026
-1,098
Period ended Jun 30, 2026
Change on a year earlier
-32.9%
-1,637 in Q2 2025
History
29 quarters
Since Q2 2019
Sources
25
Documents cited below
Where the Q2 2026 figure comes from
“|| Total adjustments to operating expenses | (1,098) | (1,637) | (2,153) | (4,058)”
Source: Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Reported in Form 8-K Reconciliations of GAAP to Non-GAAP Measures.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Amgen Total Non-GAAP Operating Expense Adjustments ($M), quarterly Q2 2019–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/ng-opex-adj
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.